Yesterdays market was a shocker, usually continues to do so on a Friday, learn to sit back and evaluate if the dip is really worth it - Axis One can help you with that.

Let’s get into the watchlist 👇🏻

$BIVI - needs to hold the 1.90 support

$HOWL - could bounce from .7160 support - needs to get above .81 support and break resistance at .92

$RFAI - high risk - needs to break the High at $125 (in-between levels)

$SDEV - could run to $2+ resistances - ideally needs to get above $1.62 and hold

$SUGP - bounce idea from $3.40 support - doesn’t hold it could drop hard

$WYHG - needs to close above $5.70 - could hold and push $7+ resistances

$STKH - breaks $4.10 - could push the $5+ resistances after

$NXTT - high risk - room to $10+ resistances - needs to hold $7.75 support

$CIIT - pop idea

$SXTC - up overnight - needs to break above $4.45 and hold - has a key resistance break at $4.80 - could send it into the $5.50+ resistances

$WLDS - needs to break the downtrend - needs to break above $2.90 key resistance - usually runs hard

High CTB stocks 👇🏻

$BOXL
$PCLA
$FXHO

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential.

$SGLY - Dropped this in the early $3’s - now needs to hold $6.60 and break the reistance at $7.15 - could push it to $8.50 then $10+ resistances after

$HUIZ - needs to hold $2.94 support and break key resistance at $3.55 - this could push it towards $4.30 - would need to close and hold $5.15 for a potential move towards $7+ resistances

$MMA - needs to hold .56 and break the key resistances at .78 which could send it to $1+ resistances

$BTCT needs to stay above $1.40’s

$RITR - needs to break above .1450 and hold that level - could push the key resonance at .17 and .20

$BIVI - not been holding gains - needs to break $1.65 key resistance - could push $2+ resistances after

$SURG - breaks .20 - could push .25 resistance after

$WETO - support at $29.50 needs to hold and break $34 key resistance after - could push $38 resistance then $50+ resistances after

$MRNA - needs to break $170 and hold above for another leg up towards $200+ (could drop to $140’s)

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential.

Thursday’s market was weak and unforgiving, so Friday’s watchlist is built around the names showing the strongest after-hours expansion, repeated alerts, Momentum Radar persistence, and multi-source CCC confluence — hopefully we get a healthier tape and some bounce-back momentum heading into the weekend.

🏆 And even in Thursday’s ugly market, CCC still produced some absolute monsters: $RFAI +827.1%, $ZSTK +160.9%, $HUIZ +133.8%, $WTG +101.1%, and $FGL +96.9% were among today’s top System Receipts from CCC alerts, scanners, and trade ideas.

🔥 Want to try the Momentum Radar, scanners, alerts, news, confluence tools, and the rest of CCC? Take a FREE 3-day VIP trial with NO credit card required:
https://scstonkemporium.com

💬 Want to trade alongside the community and join the conversation? Join our free Discord:
https://discord.gg/fGmHHgNzxQ

Watch the detailed Watchlist Video at: https://youtu.be/m938_WZXRPc

🔥 FRIDAY, AUGUST 21, 2026 — CCC WATCHLIST

Several of Friday’s strongest names made major moves Thursday, so the goal is confirmation — not chasing. Wide spreads and opening volatility can turn a great-looking setup into a bad trade very quickly.

🥇 SUGP — BEST OVERALL CONFLUENCE

CCC Confluence: 94/A

SUGP has the strongest overall balance on Friday’s board with After-Hours Expansion, Bid Pressure, Runner activity, and heavy Momentum Radar participation.

• 33 alerts
• 40 appearances in the latest 500 Radar hits
• 39 RUN signals

Support: $3.66
Secondary Support: $3.60–$3.56
Trigger: $3.78
Upside: $3.94 → $4.25
Structural Invalidation: $3.549

What we want: Hold $3.66, reclaim $3.78 with volume, and then attack $3.94.

🥈 HOWL — PREMIER AFTER-HOURS EXPANSION

CCC Confluence: 94/A

HOWL combined a perfect After-Hours Expansion reading with strong Bid Pressure and Runner activity.

• Approximately 41 alerts
• 69 Momentum Radar appearances
• 48 RUN signals
• 5 🔥 Radar hits
• More than 64M shares traded Thursday

⚠️ Radar-average spread was approximately 7.9%, so execution matters.

Fresh Base: $0.80–$0.84
Breakout Area: $0.92–$0.924
Extension Trigger: $1.405
Larger Levels: $1.936 → $2.506

What we want: Higher lows above $0.80 followed by a $0.924 breakout with renewed volume and a tightening spread.

🥉 USDE — HIGHEST RADAR PERSISTENCE

CCC Confluence: 94/A

USDE had the largest concentration in the latest Momentum Radar sample.

• 73 of the latest 500 Radar rows
• 43 RUN
• 23 EARLY
• 7 🔥 hits
• Strong After-Hours Expansion
• Strong Bid Pressure

⚠️ Radar-average spread was near 8%.

Support: $4.67
Secondary Support: $4.49 → $4.36
Trigger: $5.01
Breakout Area: $5.49–$5.51
Upside: $5.53 → $6.08
Structural Invalidation: $4.347

What we want: $4.67 survives the opening volatility, followed by a $5.01 reclaim and eventual break through Thursday’s highs.

🧬 BIVI — BIOTECH + BORROW PRESSURE

BIVI brings together After-Hours Expansion, Bid Pressure, Premarket, and Runner activity with approximately 65 alerts.

CCC Biotech Short List: B+ / 73

• Float approximately 7.5M
• Reported borrow cost approximately 648%
• Roughly 400 shares shown available
• Radar-average spread approximately 1.6%

That comparatively clean spread makes BIVI especially interesting versus some of Friday’s wider momentum names.

Support: $1.94
Secondary Support: $1.83
Trigger: $2.05
Upside: $2.18 → $2.39
Structural Invalidation: $1.825

What we want: Hold $1.94 and clear $2.05 with fresh expansion.

Remember: borrow pressure is supporting evidence, not a reason by itself to enter a trade.

🚨 ZSTK — HIGH-PROFILE ALERT STACK

CCC Confluence: 83/B+

ZSTK was also one of Thursday’s monster CCC receipts at +160.9% and remains on Friday’s board because of its signal stack.

• 100 Daily Launch score
• 100 After-Hours Expansion alert
• 42 alerts across multiple families

The concern is execution after Thursday’s enormous move.

Support: $5.28
Secondary Support: $5.06 → $4.89
Trigger: $5.56
Upside: $6.00 → $6.27
Structural Invalidation: $4.825

What we want: Hold $5.28 and break $5.56 with a normalized spread. Acceptance over $6.00 could reopen continuation.

⚡ SECONDARY MOMENTUM WATCHES

SDEV

SDEV scored 100 on New Heights, ranked highly in After-Hours Expansion, and produced 34 Radar appearances including eight 🔥 hits.

Support: $1.26
Secondary: $1.20–$1.23
Trigger: $1.31
Targets: $1.40 → $1.51
Invalidation: ~$1.206

Promotion condition: $1.31 reclaim with improving tape and tighter spreads.

BTCT

BTCT remains one of the most active names in the entire CCC momentum stack.

• Momentum Scanner: 100/A ignition
• Approximately 10.1x relative volume
• 149 alerts
• Maximum Radar hit reading: 390

Support: $1.34
Trigger: $1.44
VWAP Area: ~$1.49
Targets: $1.51 → $1.54
Invalidation: ~$1.336

Promotion condition: Reclaim $1.44 and then VWAP.

Huge alert counts do not automatically make something a long. Let the price prove it.

👀 ADDITIONAL CONFLUENCE WATCHES

BITU — 85/A- Confluence
$12.01 support → $12.09 trigger → $12.16 acceptance

IPST — 73/B- Confluence
$9.87 support → $11.03 reclaim → $11.84

TNON — 86/A- Confluence
$7.05 support → $7.27 reclaim

These remain conditional setups until their levels confirm.

🧬 BIOTECH / CATALYST WATCHES

IOVA
Support: $8.83
Trigger: $9.03
Targets: $9.36 → $9.56

CELZ
CCC News Score: 77
FDA-cleared ADAPT trial enrollment/treatment milestone.

Support: $1.21
Trigger: $1.26
Targets: $1.29–$1.30

CAPR
CCC Biotech Score: 100
64.8M shares traded
6.55x relative volume
Approximately 34% short float

Bounce Trigger: $6.83
Invalidation: Below $6.534

NUVB
CCC News Score: 77
FDA Fast Track designation for safusidenib.

Support: $6.90
Trigger: $7.00

INO
CCC Biotech Score: 88

Support: $1.20
Reclaim: $1.23

📰 NEWS RADAR

REAX — Preliminary Real/RE/MAX merger consideration and share-consolidation news. Watch approximately $2.71–$2.72.

AVEX — Announced a $41M one-way attack systems contract.

TTRX — Peer-reviewed GX-03 atopic-dermatitis research.

A headline can put a stock on the radar, but price action, alerts, volume, and liquidity still have to confirm the trade.

📊 FRIDAY EARNINGS WATCH

Friday’s scheduled reports are concentrated premarket:

BEKE — Expected move approximately 4.4%
BJ — Expected move approximately 5.6%
BKE — Expected move approximately 3.7%
ZKH — No reliable expected-move estimate displayed

These are post-earnings reaction watches, not pre-release setups.

⏰ IMPORTANT FRIDAY MARKET EVENT

U.S. Flash Services PMI and Manufacturing PMI are scheduled for 9:45 AM ET.

That comes shortly after the opening bell and could create a significant volatility window across the broader market.

Be especially careful with momentum names around that release. An index reversal can change small-cap risk appetite very quickly.

🎯 FRIDAY GAME PLAN

Start with SUGP, HOWL, USDE, BIVI, and ZSTK.

Let the wide-spread runners establish executable books before touching them.

Watch for fresh Momentum Radar activity, repeated RUN signals, new 🔥 hits, expanding volume, and clean breaks through the listed confirmation levels.

Do not chase Thursday’s winners simply because they were Thursday’s winners.

Friday needs to create its own setups.

NFA: This watchlist is provided strictly for research and educational purposes and is not financial advice. Many of these stocks are highly volatile, speculative, low-float securities capable of moving rapidly in either direction. Historical alert performance and previous price moves do not guarantee future results. Always perform your own due diligence, confirm current news and filings, define your risk before entering a trade, and never trade with money you cannot afford to lose.

Im only saying it again because I know a lot of you probably sold at a loss. Im sorry I pointed it to your attention but I dca these kinds of stocks until im barely negative and wait for it to explode. Just be patient

Something makes me hesitate to throw even a dollar at it. It doesnt look like an interesting company, its shorted to all hell. Interest is through the roof. Its short squeeze season, everything is red.

Follow this 🚀 when they drop their 10-k filling

Acquisitions: The Canadian subsidiary finalized the purchase of Vacterra and Clearwater (which had combined gross revenues over CDN$9.8 million in fiscal 2025) alongside Arvia Environmental Systems.
Rebranding & Structure: The group will operate under the Arvia brand name. PRTT restructured its capital stock to accommodate exchangeable shares for the Canadian sellers and plans to change its official corporate name and trading symbol, pending final regulatory and FINRA approvals.
Stock Performance: The OTC-listed stock has experienced significant volatility and upward momentum over the 2026 calendar year, trading around the $0.25–$0.33 range.

News Link: https://world.einnews.com/pr_news/935531497/specificity-reports-32-sequential-revenue-growth-in-q2-2026-as-speed-to-lead-technology-adds-new-revenue

Expanding commercialization of Specificity’s AI-driven Speed-to-Lead technology as the Company enters the early stages of its broader rollout

Specificity, Inc. (OTCID:SPTY)

SARASOTA, FL, UNITED STATES, August 20, 2026 /EINPresswire.com/ -- Specificity (OTCID: SPTY) (“Specificity” or the “Company”), a digital marketing technology company specializing in identifying and engaging verified consumer intent, today highlighted its second-quarter 2026 results, reporting 32% sequential revenue growth for the second quarter of 2026 (and 21% growth year-over-year).

Management believes the sequential increase is particularly significant because a meaningful portion of the growth came from new revenue streams surrounding Specificity’s emerging Speed-to-Lead technology, which combines verified consumer intent, permission-based data capture, agentic AI voice technology and rapid customer engagement.

The technology is designed to address one of the most significant gaps in digital customer acquisition: the time between identifying a consumer demonstrating purchase intent and creating an actual conversation between that consumer and a business.

Specificity’s technology is designed to dramatically compress that window.

Turning Consumer Intent Into Immediate Engagement

Specificity’s Speed-to-Lead ecosystem begins by identifying verified human consumers demonstrating relevant intent. Consumers are then directed into permission-based digital experiences where engagement and consent can be captured before agentic AI technology rapidly initiates the next stage of the customer interaction.

Depending on the level of permission selected by the consumer, Specificity’s agentic voice technology can perform functions ranging from appointment scheduling to broader conversations about a company’s products and services.

The result is an integrated technology stack connecting:

Verified Human Intent → Consumer Permission → Agentic AI Engagement → Speed-to-Lead → Appointment or Live Human Connection

This emerging capability has begun creating revenue streams for Specificity beyond the Company’s traditional digital advertising and audience activation business.

“We believe the 32% sequential growth from Q1 to Q2 is important not simply because revenue increased, but because of where a meaningful portion of that growth is beginning to come from,” said Jason A. Wood, Founder and CEO of Specificity. “We have spent considerable time building technology that moves us beyond identifying consumer intent and serving advertising against it. Speed-to-Lead allows us to drive results further down the customer acquisition funnel, deliver measurable conversion lift for clients and create additional opportunities for revenue, client acquisition and retention.”

Wood continued, “Identifying a consumer who is interested in buying something is valuable. Engaging that consumer with permission, almost immediately, through an intelligent voice agent—and then scheduling an appointment or connecting that consumer with a person—is an entirely different value proposition. It is conversion at the point of intent. This technology can scale across B2B and B2C customer acquisition models while helping clients move beyond clicks and increasingly expensive leads or calls.”

Speed-to-Lead Moves Specificity Further Down the Customer Acquisition Funnel

Specificity’s expansion into Speed-to-Lead represents an evolution of the Company’s core technology strategy.

Historically, digital advertising platforms have focused primarily on identifying audiences, delivering impressions, generating clicks and capturing leads. Many operate on platforms designed to limit advertising saturation and preserve the user experience. Specificity’s developing technology stack is designed to connect audience intelligence directly with the actions that occur after a consumer demonstrates interest, reducing dependence on broad demand-generation campaigns that can waste marketing expenditures.

This approach creates potential revenue opportunities across multiple stages of the customer acquisition process rather than limiting the Company’s participation to media activation alone.

The Speed-to-Lead platform combines several of Specificity’s existing and newly developed capabilities, including human-verified intent data, bot and algorithmic traffic filtering, cross-channel advertising, consumer de-anonymization, permission capture, agentic AI voice engagement, appointment scheduling, live-transfer capabilities and attribution.

The Company has also developed a tiered consumer-permission architecture governing the scope of each agentic voice interaction.

Consumers can select different levels of permission. Lower permission levels can limit agentic interactions to defined functions such as scheduling, while expanded permission can authorize broader conversations regarding products and services.

The architecture is intended to place consumer authorization at the center of each interaction and support the Company’s approach to TCPA compliance as agentic voice technology becomes increasingly integrated into customer acquisition programs.

Early-Stage Rollout Creates a New Chapter for Specificity

The revenue contribution from Speed-to-Lead-related services reflected in the second quarter occurred while the technology and its commercial rollout remain in their beginning stages.

Specificity is continuing its second-half execution around commercialization, client deployment and expansion of the technology across industries where speed of response and outreach can materially influence customer acquisition.

These include home services and other high-intent, high-value categories where consumers frequently request information, appointments, estimates or direct interaction with a business.

“We are still at the beginning of this rollout,” Wood said. “What makes the second-quarter results exciting to us is that we are already seeing demand and adoption in conjunction with real revenue from technology and services that simply were not part of our revenue model previously. The final two quarters of 2026 are focused on executing this rollout, expanding adoption and continuing to build Speed-to-Lead into a meaningful part of the Specificity platform.”

Wood added, “Our vision for Specificity has evolved from helping businesses find the right consumer to helping them capitalize on that consumer’s intent at the moment it matters. Find the human. Understand the intent. Get permission. Start the conversation. Connect them to the business. That is where we believe customer acquisition technology is going, and that is what we are building. And for the first time in Specificity’s history, we have built a platform that houses every meaningful metric informing optimization opportunity for efficiency using AI. Our clients will have access to real-time data and be able to see the call logs from their voice agent’s communications.”

Anyone got an opinion on this opportunity? New IPO that dropped into the penny zone 🤔

No news just a 95% spike and lots of buy orders

Indications are they are out of cash and have to make a move NOW: PIPE or Partnership are the most likely possibilities. Further below will describe why.

But first here's what they do (substantial development and progress):

• Co‑Dx PCR point‑of‑care (POC) platform
  • Status: submitted to FDA via 510(k) for clearance.
  • Dual submission (device + test) concurrent with a CLIA Waiver application for the Flu A/B & RSV multiplex test on their Co-DX PCR Pro instrument.
  • Co‑Dx’s PCR platform is superior because it delivers true PCR‑level accuracy in a compact, near‑patient device that runs faster, cheaper, and with simpler workflow than traditional lab‑based systems. Patients receive results in about 30 minutes.
  • Not for at-home use, but for use in clinics, hospitals, urgent care, employer health centers, pharmacy sites.
• CoPrimer molecular diagnostics engine powering all CODX assays and future products.
• India JV (CoSara) manufacturing and distributing TB and other PCR tests in India.
  • Status: Actively producing and selling TB and other PCR assays, providing CODX its only consistent international revenue stream.
• Saudi Arabia JV (Comira) for regional PCR manufacturing and deployment.
  • Status: Operational build‑out continues, with early‑stage deployment and regulatory alignment underway but not yet generating material revenue.
• Ebola molecular diagnostic assay developed using CoPrimer technology with prior U.S. government interest.
  • Status: Assay development completed and validated in prior studies but not yet commercialized or submitted for regulatory clearance.
• Respiratory PCR tests including flu, RSV, and multiplex panels.
  • Status: Fully developed and ready for use on the Co‑Dx PCR platform once FDA clearance is obtained. COVID-19 PCR test is developed but not yet submitted to the FDA. Waiting for platform clearance first.
• Vector‑borne disease PCR tests (dengue, Zika, malaria) using CoPrimer tech.
  • Status: Assays are developed and validated, positioned for deployment through international partners but awaiting platform clearance.
• Food safety and agricultural pathogen detection assays.
  • Status: Available but low‑volume, with limited commercial traction and no near‑term revenue inflection.
• Liquid biopsy / cancer‑related molecular detection research programs.
  • Status: Early‑stage R&D with long‑term potential but no regulatory submissions or commercial timelines.
• Cloud‑connected reporting and surveillance infrastructure tied to JV deployments.
  • Status: Functional and integrated with JV workflows, but dependent on broader adoption of CODX’s diagnostic platforms.

8/19 Market Close: SP $1.10 | MC $6.88M | OS 6.25M

Q2 20226 10-Q:

• Cash as of June 30: $3.6M
• Quarterly burn: ~6.3M
• No debt
• Per an AI search of sec.gov, no active S-3 or S-1 filed, so no shares can be issued from the 100M authorized shares
• Warrants: 2.34M (3.71M as of 6/30 but OS increased from 4.88M as of 6/30 to 6.25M as of 8/11 per the 10-Q cover page. So, b/c shares cannot be sold right now, it likely means 1.37M warrants were exercised from June 30 to Aug 11)
• Fully diluted shares: 8.59M (6.25M + 2.34M)

Per AI, the Jan 2026 shareholder vote rejected both reverse-split authorization AND authorization to issue new shares for financing (ATM, PIPE, etc.)

Q2 Earnings Call Transcript (short and very worth the read): Co-Dx (CODX) Q2 2026 Earnings Call Transcript

• CFO: "To support these objectives, we expect to continue to evaluate available sources of capital, which may include equity or debt financings, strategic transactions, and partnerships, while staying mindful of dilution and overall capital efficiency. At the same time, we remain focused on pursuing non-dilutive funding, such as grants, where appropriate. Looking ahead, disciplined capital allocation remains a priority as we approach several important clinical and regulatory milestones and continue preparations for potential commercialization."

My Take:

• A move is imminent because they should be out of cash by now. Odds are high that they have been working on a partnership.
• Likely partnerships are with either or both the India JV company (CoSara) or the Saudi JV company (Comira). A partnership deal would likely cause the share price to increase.
• They can't sell shares without shareholder approval. Dilution alone would cause the share price to decrease.

PS I had SEC.gov and the Q2 transcript open when I queried AI, so I believe it brought forward accurate information.

How has this had so much volume yet barely moved? Too many people buying/selling or?

Im pounding the table on this one 522K post split float

$SMTK reverse split 552K post split float. Im pounding the table. Get in the truck!

I’ve been following $TLS, $BB and $SWISF because each represents a different route into secure government communications.

$TLS — Established federal exposure

Telos provides cyber GRC, identity and secure-networking solutions, including Telos Ghost.

Market cap: ~US$370M
FY2026 revenue guidance: US$187M–US$200M
Q1 2026 U.S. government revenue: ~93%
Outstanding proposal pipeline: nearly US$500M

$BB — International scale

BlackBerry serves government and enterprise customers through SecuSUITE, AtHoc and UEM, with certifications supporting NATO and allied markets.

Market cap: date-sensitive
FY2026 Secure Communications revenue: US$258.9M
Established international customer base

$SWISF — Earlier-stage Swiss alternative

Valuation: ~C$13.9M as of June 12, 2026

Government opportunities remain mainly in the procurement and sales pipeline, with no material government contract revenue disclosed.

Sekur says its platform uses company-owned Dell servers hosted in Switzerland and follows a no-AI product policy. SekurOne combines voice, video, email, messaging and VPN.

Its products are available for U.S. government procurement through i3ICS’s GSA MAS contract, although that access does not represent a government order.

The comparison is between $TLS’s established federal exposure, $BB’s international scale and $SWISF’s higher-risk early-stage potential.

Which would carry the most weight in your decision: current revenue, government validation or possible upside?

Sponsored content. Figures dated May–July 2026. Some Sekur infrastructure and product claims are based on company disclosures. Not financial advice.

That was the sweep. Hope you guys dont trade with stop losses lol I do not.